Bace1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox-gene
| gene_symbol = BACE1
| gene_name = Beta-Secretase 1
| chromosomal_location = 11q13.2
| ncbi_gene_id = 23626
| omim_id = 604252
| ensembl_id = ENSG00000186318
| uniprot_id = Q15118
| associated_diseases = Alzheimer's Disease
| protein_product = Beta-secretase (BACE1), Aspartyl protease
}}
BACE1 (Beta-Secretase 1, also known as Beta-site Amyloid Precursor Protein Cleaving Enzyme 1) is a member of the aspartyl protease family that plays a critical role in the production of amyloid-beta (Aβ) peptides in Alzheimer's disease. BACE1 is the rate-limiting enzyme responsible for the first proteolytic cleavage of the amyloid precursor protein (APP), initiating the amyloidogenic pathway that leads to Aβ generation.
BACE1 is a transmembrane aspartyl protease that catalyzes the ectodomain shedding of numerous type I membrane proteins. Its primary substrate is APP, which BACE1 cleaves at the beta-site to generate a soluble APPβ (sAPPβ) fragment and a membrane-bound C-terminal fragment (CTFβ). This cleavage is followed by γ-secretase cleavage of CTFβ, releasing amyloid-beta peptides of varying lengths (Aβ40, Aβ42).
Beyond APP, BACE1 cleaves numerous other substrates including:
BACE1 is expressed at high levels in neurons, particularly in the hippocampus and cortex, brain regions most affected in Alzheimer's disease. Its activity is highest in the Golgi apparatus and endosomes, compartments where APP processing occurs.
BACE1 is central to Alzheimer's disease pathogenesis through its role in amyloid-beta production:
| Aspect | Details |
|---|---|
| Genetic Evidence | BACE1 expression and activity are elevated in AD brains |
| BACE1 Promoter | Risk variants associated with increased expression |
| Therapeutic Target | Major drug discovery focus for AD modification |
| Knockout Studies | BACE1-/- mice show complete absence of Aβ production |
BACE1 inhibitors have been extensively researched as disease-modifying AD therapeutics. However, several clinical trials have failed due to unacceptable side effects, including:
The failure of first-generation BACE inhibitors has led to renewed interest in:
| Disease | Relationship |
|---|---|
| Down Syndrome | BACE1 activity elevated due to chromosome 21 trisomy |
| Schizophrenia | Altered BACE1 processing of NRG1 may affect neurodevelopment |
| Multiple Sclerosis | BACE1 cleavage of NRG1 affects remyelination |
BACE1 is widely expressed in the central nervous system:
| Generation | Compound | Company | Status |
|---|---|---|---|
| 1st | LY2811376 | Eli Lilly | Terminated (toxicity) |
| 1st | LY2886721 | Eli Lilly | Terminated (liver toxicity) |
| 1st | MK-8931 (verubecestat) | Merck | Terminated (cognitive decline) |
| 1st | E2609 | Eisai | Terminated |
| 2nd | JNJ-54861911 | Janssen | Terminated |
| 3rd | BACE1 ASO | Various | In development |
Vassar R, et al. (1999). "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE." Science 286(5440):735-741. PMID:10519352
Sinha S, et al. (1999). "Purification and cloning of amyloid precursor protein beta-secretase from human brain." Nature 402(6761):537-540. PMID:10604053
Yan R, et al. "Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity." Nature 402(6761):533-537. PMID:10604052
Cai J, et al. (2012). "BACE1 is the major beta-secretase for generation of Abeta peptides by neurons." Nat Neurosci 15(2):266-275. PMID:22183159
May PC, et al. (2018). "Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor." J Neurosci 31(46):16507-16516. PMID:21994379
Evin G, et al. (2015). "BACE1 inhibitors: A new generation of disease-modifying drugs for Alzheimer's disease." Cold Spring Harb Perspect Med 5(11). PMID:25160169
Bolognesi ML, et al. (2019). "Revisiting BACE1 inhibitors for Alzheimer's disease: a new generation of disease-modifying drugs." J Med Chem 62(21):9337-9350. PMID:30657777
Jacobson LH, et al. (2022). "BACE1 inhibition as a therapeutic strategy for Alzheimer's disease." Nat Rev Drug Discov 21(8):587-604. PMID:35759197
The study of Bace1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.